16 September 2026 editorial review · Item
Finerenone (Kerendia) for T1D kidney disease: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Finerenone (Kerendia) for T1D kidney disease
Scope and findings:
- Primary company release confirms priorityreview,T1DCKDindication investigational,UACRsurrogate6 months;registrycompleted241. Septemberhorizon found non-diabeticFINDCKD update,notT1approval. Existing correctsurrogate caveat retained; no newhardoutcomeclaim.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.